AngioDynamics (NASDAQ:ANGO) Releases FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of -0.380–0.340 for the period, compared to the consensus earnings per share estimate of -0.400. The company issued revenue guidance of $282.0 million-$288.0 million, compared to the consensus revenue estimate of $283.9 million. AngioDynamics also updated its FY25 guidance to ($0.38)-($0.34) EPS.

AngioDynamics Trading Up 37.7 %

Shares of NASDAQ:ANGO opened at $12.94 on Thursday. The company has a market capitalization of $525.80 million, a price-to-earnings ratio of -2.12 and a beta of 0.59. The business has a 50-day moving average price of $7.99 and a 200 day moving average price of $7.34. AngioDynamics has a 12-month low of $5.26 and a 12-month high of $13.13.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The firm had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The firm’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter last year, the company posted ($0.05) EPS. As a group, equities research analysts predict that AngioDynamics will post -0.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on ANGO. Canaccord Genuity Group lowered their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of AngioDynamics in a research note on Tuesday, December 10th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.